keyword
MENU ▼
Read by QxMD icon Read
search

mRcc

keyword
https://www.readbyqxmd.com/read/28810837/phase-i-dose-escalation-study-of-pazopanib-combined-with-bevacizumab-in-patients-with-metastatic-renal-cell-carcinoma-or-other-advanced-tumors
#1
Sylvie Négrier, David Pérol, Rastislav Bahleda, Antoine Hollebecque, Etienne Chatelut, Helen Boyle, Philippe Cassier, Séverine Metzger, Ellen Blanc, Jean-Charles Soria, Bernard Escudier
BACKGROUND: Vascular endothelial growth factor (VEGF) directed therapies are being used in a large number of advanced tumors. Metastatic renal cell carcinoma (mRCC) is highly dependent on the VEGF pathway; VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKI) and humanized VEGF monoclonal antibody have been registered for clinical use in advanced renal cell carcinoma. The VEGFR TKI, pazopanib, with a rather manageable toxicity profile, was preferred to sunitinib by mRCC patients. We investigate the combination of pazopanib and bevacizumab to determine the maximum tolerated dose (MTD) in mRCC and other advanced solid tumors...
August 15, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28801802/does-dose-modification-affect-efficacy-of-first-line-pazopanib-in-metastatic-renal-cell-carcinoma
#2
Paolo Grassi, Elena Verzoni, Raffaele Ratta, Luca Porcu, Michele Prisciandaro, Alessia Mennitto, Giuseppina Calareso, Filippo de Braud, Giuseppe Procopio
BACKGROUND: Pazopanib is a standard treatment for metastatic renal cell carcinoma (mRCC), and 800 mg/daily is considered the optimal dose. However, some patients require dose modification because of toxicity. Whether a reduced dose of pazopanib is as effective as the standard dose in achieving clinical benefit remains unclear. OBJECTIVES: Our objective was to conduct a retrospective analysis to investigate the clinical effect of different therapeutic doses of first-line pazopanib in patients with mRCC...
August 11, 2017: Drugs in R&D
https://www.readbyqxmd.com/read/28796163/hypertension-caused-by-lenvatinib-and-everolimus-in-the-treatment-of-metastatic-renal-cell-carcinoma
#3
REVIEW
Mathias Alrø Fichtner Bendtsen, Daniela Grimm, Johann Bauer, Markus Wehland, Petra Wise, Nils E Magnusson, Manfred Infanger, Marcus Krüger
Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor everolimus proved effective when applied alone, but more effective when they were administered combined. Recently, both drugs were included in clinical trials, resulting in international clinical guidelines for the treatment of mRCC...
August 10, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28790354/early-skeletal-muscle-loss-during-target-therapy-is-a-prognostic-biomarker-in-metastatic-renal-cell-carcinoma-patients
#4
Weijie Gu, Junlong Wu, Xiaohang Liu, Hailiang Zhang, Guohai Shi, Yao Zhu, Dingwei Ye
Skeletal muscle depletion is common in patients with advanced cancer and may be associated with a poor outcome. To investigate whether the changes in skeletal muscle in metastatic renal cell carcinoma (mRCC) patients receiving targeted therapy are associated with clinical outcome, we undertook an observational cohort study using data from a number of randomized clinical trials previously conducted at the Fudan University Shanghai Cancer Center. The muscle mass was evaluated by comparing computed tomography images obtained at baseline with those obtained after 3-4 months of treatment...
August 8, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28789709/comparison-of-efficacy-safety-and-quality-of-life-between-sorafenib-and-sunitinib-as-first-line-therapy-for-chinese-patients-with-metastatic-renal-cell-carcinoma
#5
Wen Cai, Wen Kong, Baijun Dong, Jin Zhang, Yonghui Chen, Wei Xue, Yiran Huang, Lixin Zhou, Jiwei Huang
BACKGROUND: Sorafenib and sunitinib are widely used as first-line targeted therapy for metastatic renal cell carcinoma (mRCC) in China. This study aimed to compare the efficacy, safety, and quality of life (QoL) in Chinese mRCC patients treated with sorafenib and sunitinib as first-line therapy. METHODS: Clinical data of patients with mRCC who received sorafenib (400 mg twice daily; 4 weeks) or sunitinib (50 mg twice daily; on a schedule of 4 weeks on treatment followed by 2 weeks off) were retrieved...
August 8, 2017: Chinese Journal of Cancer
https://www.readbyqxmd.com/read/28781819/progression-free-survival-of-first-line-treatment-with-molecular-targeted-therapy-may-be-a-meaningful-intermediate-endpoint-for-overall-survival-in-patients-with-metastatic-renal-cell-carcinoma
#6
Nobuki Furubayashi, Takahito Negishi, Takuya Yamashita, Shuhei Kusano, Kenichi Taguchi, Mototsugu Shimokawa, Motonobu Nakamura
The aim of the present study was to investigate the association between clinical parameters and the overall survival (OS) of Japanese patients with metastatic renal cell carcinoma (mRCC). The medical records of 59 consecutive mRCC patients receiving molecular-targeted therapy were retrospectively assessed. Kaplan-Meier and log-rank analyses were used to evaluate the progression-free survival (PFS) and OS, and a multivariate Cox proportional hazard model was used to analyze the clinical parameters for their prognostic relevance...
September 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28780300/observation-after-cytoreductive-nephrectomy-in-patients-with-synchronous-not-completely-resected-metastases-of-renal-cell-carcinoma
#7
Roderick E de Bruijn, Teele Kuusk, Allard P Noe, Christian U Blank, John B A G Haanen, Kees Hendricksen, Simon Horenblas, Axel Bex
OBJECTIVE: To determine the time-to-targeted therapy (TTT) in patients with not completely resected low-volume oligometastatic disease who were observed following debulking cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS: Patients with sychronous mRCC with not completely resected low-volume metastases and in whom observation after CN was a multidisciplinary tumour board recommendation were identified from an approved institutional database...
August 2, 2017: Urology
https://www.readbyqxmd.com/read/28753824/body-composition-in-relation-to-clinical-outcomes-in-renal-cell-cancer-a-systematic-review-and-meta-analysis
#8
REVIEW
Alina Vrieling, Ellen Kampman, Nathalja C Knijnenburg, Peter F Mulders, J P Michiel Sedelaar, Vickie E Baracos, Lambertus A Kiemeney
CONTEXT: Several studies suggest that body composition (ie, body proportions of muscle and fat defined by computed tomography) is associated with clinical outcomes of several cancer types, including renal cell cancer (RCC). OBJECTIVE: To conduct a systematic review and meta-analysis of the evidence on body composition in relation to clinical outcomes in RCC. EVIDENCE ACQUISITION: Literature was reviewed through October 2016 using PubMed and Embase...
December 4, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28748721/real-world-costs-and-outcomes-in-metastatic-renal-cell-carcinoma-patients-treated-with-targeted-therapies-a-cohort-study-from-the-french-health-insurance-database
#9
Rana Maroun, Laetitia Fleury, Gaelle Nachbaur, Franck Maunoury, Jean-Louis Vanhille, Isabelle Durand-Zaleski
OBJECTIVES: The objective of this study was to describe treatment patterns, survival, healthcare use and costs in patients with metastatic renal cell carcinoma (mRCC) in a real-world setting. RESEARCH DESIGN AND METHODS: We used the National Health Insurance (NHI) claims database for the Ile-de-France region to perform a retrospective cohort analysis of patients with mRCC treated by a first-line targeted therapy. Treatment naïve patients were identified combining the 10th revision of the International Classification of Diseases (ICD-10) codes (C64 & C77-C79) and a first prescription of targeted therapies...
August 7, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28740436/the-effect-of-apatinib-in-the-treatment-of-metastatic-renal-cell-carcinoma-a-case-report-and-review-of-the-literature
#10
Jinling Bi, Haiyuan Liu, Yong Huang
The aim of this study was to explore the effect of apatinib in the treatment of metastatic renal cell carcinoma (mRCC) and related adverse events. A case of mRCC was reported which recurred after surgery and roferon treatment. The patient was treated with apatinib at a dose of 500 mg orally, twice daily, 28 days/cycle. The metastatic lesions improved based on computed tomography after apatinib administration in the fourth and eighth month. The progression-free survival of the patient had increased almost to 8 months...
2017: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/28733795/early-response-of-c-reactive-protein-as-a-predictor-of-survival-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-tyrosine-kinase-inhibitors
#11
Yosuke Yasuda, Kazutaka Saito, Takeshi Yuasa, Sho Uehara, Naoko Kawamura, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Shinya Yamamoto, Tetsuo Okuno, Junji Yonese, Kazunori Kihara, Yasuhisa Fujii
BACKGROUND: Pretreatment C-reactive protein (CRP) has been shown to be an independent prognostic factor for metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). We further evaluated the early response of CRP after the initiation of TKIs. METHODS: A total of 103 patients (80 men and 23 women) were treated with TKIs for mRCC from 2008-2013. Patients were divided into three groups according to their early CRP kinetics-patients whose baseline CRP levels were <10 mg/L (non-elevated), patients whose baseline CRP levels were ≥10 mg/L and had decreased by >20% at 4 weeks after the initiation of TKIs (early CRP responder), and the remaining patients (non-early CRP responder)...
July 21, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28731496/prognostic-factors-for-survival-in-metastatic-renal-cell-carcinoma-patients-with-brain-metastases-receiving-targeted-therapy
#12
Ibrahim Yildiz, Ahmet Bilici, Nuri Karadurmuş, Leyla Ozer, Deniz Tural, Mehmet A Kaplan, Tülay Akman, Ibrahim V Bayoglu, Mükremin Uysal, Yaşar Yildiz, Özgür Tanriverdi, Ozan Yazici, Zeki Sürmeli, Nazim Serdar Turhal, Sevil Bavbek, Fatih Selçukbiricik, Doğan Koca, Mert Basaran
BACKGROUND: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. PATIENTS AND METHODS: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. RESULTS: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70...
July 14, 2017: Tumori
https://www.readbyqxmd.com/read/28723499/prospective-evaluation-of-the-impact-of-antiangiogenic-treatment-on-cognitive-functions-in-metastatic-renal-cancer
#13
Florence Joly, Natacha Heutte, Brigitte Duclos, Sabine Noal, Isabelle Léger-Hardy, Sarah Dauchy, Nadine Longato, Laurence Desrues, Nadine Houede, Marie Lange, Emmanuel Sevin, Chantal Rieux, Bénédicte Clarisse, Hélène Castel, Bernard Escudier
BACKGROUND: Little is known about the cognitive effects of antiangiogenic therapies (AATs) in metastatic renal cell carcinoma (mRCC) and their relation with fatigue. OBJECTIVE: To evaluate the impact of AATs on cognition and its connection with fatigue and quality of life (QoL) in patients with mRCC. DESIGN, SETTING, AND PARTICIPANTS: This prospective study enrolled 75 patients starting AAT as first or second line for mRCC and assessed them at 3 mo (n=58) and 6 mo (n=50)...
December 15, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723497/pharmacogenomic-markers-of-targeted-therapy-toxicity-in-patients-with-metastatic-renal-cell-carcinoma
#14
Guillermo de Velasco, Kathryn P Gray, Lana Hamieh, Yuksel Urun, Hallie A Carol, Andre P Fay, Sabina Signoretti, David J Kwiatkowski, David F McDermott, Matthew Freedman, Mark M Pomerantz, Toni K Choueiri
BACKGROUND: Targeted therapy (TT) in metastatic renal cell carcinoma (mRCC) may be associated with a high rate of toxicity that undermines treatment efficacy and patient quality of life. Polymorphisms in genes involved in the pharmacokinetic pathways of TTs may predict toxicity. OBJECTIVE: To investigate whether selected single-nucleotide polymorphisms (SNPs) in three core genes involved in the metabolism and transport of sunitinib and the mTOR inhibitors everolimus and temsirolimus are associated with adverse events (AEs)...
December 15, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28723377/external-validation-of-the-mskcc-and-imdc-risk-models-in-patients-treated-with-targeted-therapy-as-a-first-line-and-subsequent-second-line-treatment-a-japanese-multi-institutional-study
#15
Nobuyuki Tanaka, Ryuichi Mizuno, Keiichi Ito, Suguru Shirotake, Yota Yasumizu, Ayako Masunaga, Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Ken Nakagawa, Tetsuo Momma, Takeshi Masuda, Tomohiko Asano, Masafumi Oyama, Mototsugu Oya
BACKGROUND: Two risk models, the Memorial Sloan Kettering Cancer Center (MSKCC) model and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model, have been studied in metastatic renal cell carcinoma (mRCC) treated with targeted therapy. OBJECTIVE: To validate externally the predictive accuracies of the MSKCC and IMDC models for prognosis in mRCC patients treated with first-line and subsequent second-line targeted therapy. DESIGN, SETTING, AND PARTICIPANTS: A total of 311 patients were assessed retrospectively...
August 2016: European Urology Focus
https://www.readbyqxmd.com/read/28721060/clinical-use-of-lenvatinib-in-combination-with-everolimus-for-the-treatment-of-advanced-renal-cell-carcinoma
#16
REVIEW
Alessandro Leonetti, Francesco Leonardi, Melissa Bersanelli, Sebastiano Buti
INTRODUCTION: Renal cell carcinoma (RCC) represents 2%-3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target of rapamycin (mTOR) inhibitor everolimus, for the treatment of metastatic RCC (mRCC). AIM: The objective of this article is to review the evidence about the treatment of mRCC with combination of lenvatinib plus everolimus...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28711490/long-term-response-to-sunitinib-treatment-in-metastatic-renal-cell-carcinoma-a-pooled-analysis-of-clinical-trials
#17
Nizar M Tannir, Robert A Figlin, Martin E Gore, M Dror Michaelson, Robert J Motzer, Camillo Porta, Brian I Rini, Caroline Hoang, Xun Lin, Bernard Escudier
BACKGROUND: We characterized clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib who were long-term responders (LTRs), defined as patients having progression-free survival (PFS) > 18 months. PATIENTS AND METHODS: A retrospective analysis of data from 5714 patients with mRCC treated with sunitinib in 8 phase II/III clinical trials and the expanded access program. Duration on-study and objective response rate (ORR) were compared between LTRs and patients with PFS ≤ 18 months ("others")...
June 20, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28702843/cytoreductive-nephrectomy-in-patients-with-metastatic-renal-cell-carcinoma-in-the-era-of-targeted-therapy-a-bibliographic-review
#18
REVIEW
Oscar Rodriguez Faba, Sabine D Brookman-May, Estefania Linares, Alberto Breda, Francesca Pisano, José Daniel Subiela, Francesco Sanguedolce, Maurizio Brausi, Joan Palou
PURPOSE: To evaluate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC), against a background of lack of evidence following the introduction of targeted therapy. METHODS: A literature review was performed in January 2017 using the MEDLINE/PubMed and EMBASE databases. The PRISMA guidelines were followed for conduct of the study. Two authors independently screened the 270 papers retrieved from the search, and the finally selected publications were identified by consensus between the two reviewers...
July 12, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28683470/integrating-cytokines-and-angiogenic-factors-and-tumour-bulk-with-selected-clinical-criteria-improves-determination-of-prognosis-in-advanced-renal-cell-carcinoma
#19
A J Zurita, R C Gagnon, Y Liu, H T Tran, R A Figlin, T E Hutson, A M D'Amelio, C N Sternberg, L N Pandite, J V Heymach
BACKGROUND: In two clinical trials of the vascular endothelial growth factor (VEGF) receptor inhibitor pazopanib in advanced renal cell carcinoma (mRCC), we found interleukin-6 as predictive of pazopanib benefit. We evaluated the prognostic significance of candidate cytokines and angiogenic factors (CAFs) identified in that work relative to accepted clinical parameters. METHODS: Seven preselected plasma CAFs (interleukin-6, interleukin-8, osteopontin, VEGF, hepatocyte growth factor, tissue inhibitor of metalloproteinases (TIMP-1), and E-selectin) were measured using multiplex ELISA in plasma collected pretreatment from 343 mRCC patients participating in the phase 3 registration trial of pazopanib vs placebo (NCT00334282)...
August 8, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28682093/national-institutes-of-health-research-plan-on-rehabilitation
#20
(no author information available yet)
One in 5 Americans experiences disability that affects daily function because of impairments in mobility, impairments in cognitive function, sensory impairment, or communication impairment. The need for rehabilitation strategies to optimize function and reduce disability is a clear priority for research to address this public health challenge. The National Institutes of Health (NIH) recently published a Research Plan on Rehabilitation that provides a set of priorities to guide the field over the next 5 years (Eunice Kennedy Shriver National Institute of Child Health and Human Development [NICHD] & NIH Medical Rehabilitation Coordinating Committee [MRCC], 2016)...
July 6, 2017: Rehabilitation Psychology
keyword
keyword
77808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"